Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EPS (Weighted Average and Diluted) (2022 - 2025)

Autolus Therapeutics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.34 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 277.78% year-over-year to -$0.34; the TTM value through Dec 2025 reached -$1.08, down 25.58%, while the annual FY2025 figure was -$1.08, 25.58% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.34 in Q4 2025 per AUTL's latest filing, down from -$0.3 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.09 in Q4 2024 to a low of -$0.47 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.29, with a median of -$0.26 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 80.0% in 2024, then plummeted 277.78% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.23 in 2022, then plummeted by 95.65% to -$0.45 in 2023, then surged by 80.0% to -$0.09 in 2024, then tumbled by 277.78% to -$0.34 in 2025.
  • Per Business Quant, the three most recent readings for AUTL's EPS (Weighted Average and Diluted) are -$0.34 (Q4 2025), -$0.3 (Q3 2025), and -$0.18 (Q2 2025).